Novartis, Mylan Settle Feud Over Generic Vivelle-Dot

Law360, New York (November 21, 2011, 7:09 PM EST) -- Drugmakers Novartis AG and Mylan Inc. have settled patent litigation over Mylan's bid to produce a generic version of Novartis' estrogen therapy drug Vivelle-Dot, which will allow the generic to be manufactured, Mylan announced Monday.

Under the settlement, Novartis will drop its lawsuits in New York and Vermont against Mylan and Mylan will receive a patent license to begin selling its generic version of Vivelle-Dot beginning in December 2013, subject to the approval by the U.S. Department of Justice and the Federal Trade Commission, according to...
To view the full article, register now.